…,836 per MS patient with mild disability (EDSS < 3), $46,622 per patient with moderate disability (EDSS 4-6.5), and $77,981 per patient with severe disability (EDSS score 7-9) (Karampampa et al. J Popul Ther Clin Pharmacol 2012;19:e11-25; free full text at www.jptcp.com/jptcp11072e11_e25_karampampa-pdf-r180364). The estimated cost per relapse for an RRMS patient (EDSS < 5) was $10,512. Subscribe to read more It takes 30 seconds or login using your…
…An Australian study reports that patients with mild to moderate Alzheimer’s disease are at increased risk of falls compared to age-matched controls (Suttanon et al. Am J Phys Med Rehabil 2012;91:12-23). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
A number of prospective studies have suggested that elevated serum total homocysteine (tHcy), and low folate and vitamin B12 levels are a risk factor for Alzheimer’s disease (Clarke et al. Arch Neurol 1998; 55: 1449-1455). In the Prospective Population Study of Women in Gothenburg, elevated tHcy in midlife was associated with a hazard ratio of 2.1 for developing AD and 2.4 for AD with no cerebrovascular disease (Zylberstein et al. Neurobiol Aging…
…A majority of patients with psychiatric comorbidities secondary to tuberous sclerosis complex (TSC) respond to psychoactive medications, according to a single-centre analysis of clinical records (Chung et al. Ann Clin Psychiatry 2011; 23: 263-269). Subscribe to read more It takes 30 seconds or login using your email address Please enter the email address that you registered the newsletter with Continue…
Two novel compounds currently in development – bapineuzumab and solanezumab – for the treatment of Alzheimer’s disease expect to release phase III data in 2012. Those results may usher in a new era, or may add names to the list of high-profile setbacks in AD therapeutics such as tarenflurbil (Myriad), semagacestat (Lilly/Elan), tramiprosate (Neurochem) and AN1792 (Elan). Subscribe to read more It takes 30 seconds or login using your email address…